首页 > 最新文献

Medicine Advances最新文献

英文 中文
Effectiveness of Remote Glucose Monitoring Versus Conventional Care in Diabetes Management: A Systematic Review and Meta-Analysis 远程血糖监测与常规护理在糖尿病管理中的有效性:系统回顾和荟萃分析
Pub Date : 2025-03-24 DOI: 10.1002/med4.70008
Peter Olujimi Odutola, Peter Oluwatobi Olorunyomi, Olanrewaju Olamide Olatawura, Ifeoluwapo Olorunyomi

Diabetes mellitus, especially type 2 diabetes (T2DM), is a growing global health issue characterized by poor blood glucose control, leading to severe complications and increased healthcare costs. Effective management requires accessible, responsive support systems to enhance self-management, particularly for those with limited access to traditional care. The aim was to evaluate remote monitoring versus standard care in managing diabetes mellitus, focusing on outcomes like Hemoglobin A1C (HbA1C) levels, fasting blood glucose (FBG), lipid profiles, body weight, body mass index (BMI), and blood pressure. A comprehensive literature search was performed in September 2024 using the Cochrane, Google Scholar, and PubMed databases with no time restriction. Seven studies totaling 883 participants were included, comparing remote monitoring with usual care in diabetic management. Data were analyzed using Review Manager (Cochrane), calculating mean differences and 95% confidence intervals (CIs) for continuous data, with statistical significance at p < 0.05. Remote monitoring significantly improved glycemic control, reducing HbA1c levels (mean difference: −0.35; 95% CI: −0.67 to −0.02; p = 0.04) and FBG (mean difference: −0.82; 95% CI: −1.10 to −0.54; p < 0.00001). Total cholesterol levels decreased significantly (mean difference: −0.28; 95% CI: −0.49 to −0.07; p = 0.01). HDL showed a minor but significant decline, while LDL reduction was non-significant. No significant differences were observed in body weight, BMI, or blood pressure. Remote monitoring shows significant potential in improving glycemic control and lipid profiles in diabetes management. Further long-term studies are needed to validate these findings, while addressing associated technological challenges.

糖尿病,特别是2型糖尿病(T2DM),是一个日益严重的全球健康问题,其特点是血糖控制不良,导致严重并发症和医疗保健费用增加。有效的管理需要可获得的、反应迅速的支持系统,以加强自我管理,特别是对那些获得传统护理机会有限的人。目的是评估远程监测与标准护理在糖尿病管理中的作用,重点关注血红蛋白A1C (HbA1C)水平、空腹血糖(FBG)、脂质谱、体重、体重指数(BMI)和血压等结果。我们于2024年9月使用Cochrane、b谷歌Scholar和PubMed数据库进行了全面的文献检索,没有时间限制。共纳入7项研究,共883名参与者,比较糖尿病管理中的远程监测与常规护理。使用Review Manager (Cochrane)对数据进行分析,计算连续数据的平均差异和95%置信区间(ci), p <;0.05. 远程监测可显著改善血糖控制,降低HbA1c水平(平均差值:- 0.35;95% CI:−0.67 ~−0.02;p = 0.04)和FBG(平均差值:−0.82;95% CI:−1.10 ~−0.54;p & lt;0.00001)。总胆固醇水平显著降低(平均差异:−0.28;95% CI:−0.49 ~−0.07;p = 0.01)。HDL有轻微但显著的下降,而LDL的下降不显著。在体重、身体质量指数或血压方面没有观察到显著差异。远程监测在改善糖尿病管理中的血糖控制和血脂方面显示出巨大的潜力。需要进一步的长期研究来验证这些发现,同时解决相关的技术挑战。
{"title":"Effectiveness of Remote Glucose Monitoring Versus Conventional Care in Diabetes Management: A Systematic Review and Meta-Analysis","authors":"Peter Olujimi Odutola,&nbsp;Peter Oluwatobi Olorunyomi,&nbsp;Olanrewaju Olamide Olatawura,&nbsp;Ifeoluwapo Olorunyomi","doi":"10.1002/med4.70008","DOIUrl":"https://doi.org/10.1002/med4.70008","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Diabetes mellitus, especially type 2 diabetes (T2DM), is a growing global health issue characterized by poor blood glucose control, leading to severe complications and increased healthcare costs. Effective management requires accessible, responsive support systems to enhance self-management, particularly for those with limited access to traditional care. The aim was to evaluate remote monitoring versus standard care in managing diabetes mellitus, focusing on outcomes like Hemoglobin A1C (HbA1C) levels, fasting blood glucose (FBG), lipid profiles, body weight, body mass index (BMI), and blood pressure. A comprehensive literature search was performed in September 2024 using the Cochrane, Google Scholar, and PubMed databases with no time restriction. Seven studies totaling 883 participants were included, comparing remote monitoring with usual care in diabetic management. Data were analyzed using Review Manager (Cochrane), calculating mean differences and 95% confidence intervals (CIs) for continuous data, with statistical significance at <i>p</i> &lt; 0.05. Remote monitoring significantly improved glycemic control, reducing HbA1c levels (mean difference: −0.35; 95% CI: −0.67 to −0.02; <i>p</i> = 0.04) and FBG (mean difference: −0.82; 95% CI: −1.10 to −0.54; <i>p</i> &lt; 0.00001). Total cholesterol levels decreased significantly (mean difference: −0.28; 95% CI: −0.49 to −0.07; <i>p</i> = 0.01). HDL showed a minor but significant decline, while LDL reduction was non-significant. No significant differences were observed in body weight, BMI, or blood pressure. Remote monitoring shows significant potential in improving glycemic control and lipid profiles in diabetes management. Further long-term studies are needed to validate these findings, while addressing associated technological challenges.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"28-36"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming Computational Resource Limitations in Deep Learning for Healthcare: Strategies Targeting Data, Model, and Computing 克服医疗保健深度学习中的计算资源限制:针对数据、模型和计算的策略
Pub Date : 2025-03-23 DOI: 10.1002/med4.70001
Han Yuan

Deep learning has been identified as an indispensable backbone in health data science. However, the computational constraints faced by many healthcare providers, who may lack access to high-performance computing resources, must be considered. This commentary illustrates three representative strategies from the perspective of data, model, and computing to mitigate computational constraints in resource-limited settings.

深度学习已经被认为是健康数据科学中不可或缺的支柱。但是,必须考虑许多医疗保健提供商面临的计算限制,他们可能无法访问高性能计算资源。这篇评论从数据、模型和计算的角度阐述了在资源有限的环境中减轻计算约束的三种代表性策略。
{"title":"Overcoming Computational Resource Limitations in Deep Learning for Healthcare: Strategies Targeting Data, Model, and Computing","authors":"Han Yuan","doi":"10.1002/med4.70001","DOIUrl":"https://doi.org/10.1002/med4.70001","url":null,"abstract":"<p>Deep learning has been identified as an indispensable backbone in health data science. However, the computational constraints faced by many healthcare providers, who may lack access to high-performance computing resources, must be considered. This commentary illustrates three representative strategies from the perspective of data, model, and computing to mitigate computational constraints in resource-limited settings.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"42-45"},"PeriodicalIF":0.0,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alone in the Mind: Review of Research Examining the Link Between Loneliness and Dementia 心灵中的孤独:孤独与痴呆之间联系的研究综述
Pub Date : 2025-03-17 DOI: 10.1002/med4.70005
Ahmed Hussein Al-Samiry, Samer Imad Mohammed, Ahmed Majid Hammed, Tayf M. Maryoosh

This narrative review focused on research investigating the impact of loneliness on the prevalence of dementia and its relationship with other risk factors. A comprehensive and rigorous search was conducted using a variety of scientific databases with specific keywords to identify all prior studies that examined the correlation between dementia and loneliness. The inquiry was confined to articles published in English from January 2017 to March 2024. The narrative review identified a consensus regarding the role of loneliness in enhancing the risk of all-cause dementia, with a particular emphasis on the subjective perception of loneliness. This phenomenon may be caused by the sensations of exclusion, discrimination, and alienation that are typically associated with low self-esteem and low life satisfaction, which may contribute to cognitive impairment and depressive symptoms. This finding was obtained despite the absence of robust evidence regarding the involvement of loneliness in the pathogenesis of dementia. Existing research has not yet identified a correlation between hereditary factors that influence the development of dementia and feelings of loneliness. However, loneliness is strongly associated with depression, which is a potential risk factor for dementia. Previous studies have reported a moderate correlation between depression and loneliness, as individuals who are isolated and lack a sense of community exhibit higher levels of depression. Meditation, social cognitive training, and social support are three strategies that have been implemented to address loneliness and are reported to be the most effective interventions. A strong correlation exists between dementia and loneliness. Although such strategies are unlikely to impede the progression of the disease if cognitive deterioration is already underway, understanding these associations can assist in the development of strategies to alleviate the effects of loneliness on vulnerable individuals.

这篇叙述性综述的重点是研究孤独对痴呆患病率的影响及其与其他风险因素的关系。研究人员利用各种科学数据库进行了全面而严格的搜索,其中包含特定的关键词,以确定之前所有研究痴呆症和孤独之间关系的研究。此次调查仅限于2017年1月至2024年3月期间发表的英文文章。叙述性综述确定了关于孤独在增加全因痴呆风险中的作用的共识,特别强调了对孤独的主观感知。这种现象可能是由排斥、歧视和疏远的感觉引起的,这些感觉通常与低自尊和低生活满意度有关,这可能导致认知障碍和抑郁症状。这一发现是在缺乏关于孤独在痴呆发病机制中的作用的有力证据的情况下获得的。现有的研究尚未确定影响痴呆症发展和孤独感的遗传因素之间的相关性。然而,孤独与抑郁密切相关,而抑郁是痴呆的潜在风险因素。先前的研究报告了抑郁和孤独之间的适度关联,因为孤立和缺乏社区意识的个体表现出更高程度的抑郁。冥想、社会认知训练和社会支持是解决孤独的三种策略,据报道,这是最有效的干预措施。痴呆和孤独之间存在很强的相关性。虽然如果认知退化已经开始,这些策略不太可能阻止疾病的进展,但了解这些关联可以帮助制定减轻孤独感对脆弱个体影响的策略。
{"title":"Alone in the Mind: Review of Research Examining the Link Between Loneliness and Dementia","authors":"Ahmed Hussein Al-Samiry,&nbsp;Samer Imad Mohammed,&nbsp;Ahmed Majid Hammed,&nbsp;Tayf M. Maryoosh","doi":"10.1002/med4.70005","DOIUrl":"https://doi.org/10.1002/med4.70005","url":null,"abstract":"<p>This narrative review focused on research investigating the impact of loneliness on the prevalence of dementia and its relationship with other risk factors. A comprehensive and rigorous search was conducted using a variety of scientific databases with specific keywords to identify all prior studies that examined the correlation between dementia and loneliness. The inquiry was confined to articles published in English from January 2017 to March 2024. The narrative review identified a consensus regarding the role of loneliness in enhancing the risk of all-cause dementia, with a particular emphasis on the subjective perception of loneliness. This phenomenon may be caused by the sensations of exclusion, discrimination, and alienation that are typically associated with low self-esteem and low life satisfaction, which may contribute to cognitive impairment and depressive symptoms. This finding was obtained despite the absence of robust evidence regarding the involvement of loneliness in the pathogenesis of dementia. Existing research has not yet identified a correlation between hereditary factors that influence the development of dementia and feelings of loneliness. However, loneliness is strongly associated with depression, which is a potential risk factor for dementia. Previous studies have reported a moderate correlation between depression and loneliness, as individuals who are isolated and lack a sense of community exhibit higher levels of depression. Meditation, social cognitive training, and social support are three strategies that have been implemented to address loneliness and are reported to be the most effective interventions. A strong correlation exists between dementia and loneliness. Although such strategies are unlikely to impede the progression of the disease if cognitive deterioration is already underway, understanding these associations can assist in the development of strategies to alleviate the effects of loneliness on vulnerable individuals.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"20-27"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diacerein's Role in Alleviating Inflammation and Synovial Effusion in Knee Osteoarthritis: A Novel Therapeutic Approach 膝骨性关节炎:一种新的治疗方法:地塞骨素在缓解炎症和滑膜积液中的作用
Pub Date : 2025-03-12 DOI: 10.1002/med4.70004
Saim Mahmood Khan, Marium Amjad, Rida Shakil, Eisha Shoaib, Dong Hwi Kim, Jawairya Muhammad Hussain

Diacerein, an anthraquinone derivative, has gained interest in recent years as a potential therapeutic agent in the management of knee osteoarthritis (KOA), particularly the inflammatory subtype effusion synovitis. This commentary evaluates the effect of diacerein on KOA symptoms and functional outcomes of recent parts of a multicenter randomized controlled trial. The clinical trial of diacerein as a monotherapy for effusion synovitis concluded that not only was there no overall significant change in the knee joint's moisture content after a 24-week therapy but also there was no evidence of symptomatic or functional improvement. Furthermore, problems like diarrhea and colored urine raised questions about its safety and user-friendly profile; therefore, these findings were contentious. These outcomes highlight the need for greater investigation of diacerein, including in combination therapies where its benefits are amplified and adverse effects diminished. Further research should help to define diacerein's role in KOA treatment and increase the understanding of its actions regarding effusion synovitis, focusing on side effects.

双醋瑞因是一种蒽醌衍生物,近年来作为治疗膝骨关节炎(KOA),尤其是炎症亚型渗出性滑膜炎的潜在治疗药物而备受关注。这篇评论评估了 diacerein 对 KOA 症状的影响以及多中心随机对照试验近期部分的功能结果。迪卡瑞林作为单一疗法治疗渗出性滑膜炎的临床试验结果表明,经过 24 周的治疗后,膝关节的含水量不仅没有整体上的显著变化,而且也没有症状或功能改善的证据。此外,腹泻和有色尿液等问题也对其安全性和用户友好性提出了质疑;因此,这些研究结果是有争议的。这些结果突出表明,有必要对泻肝素进行更深入的研究,包括在联合疗法中,因为在联合疗法中,泻肝素的益处会更大,而不良反应会更小。进一步的研究应有助于确定迪卡瑞林在 KOA 治疗中的作用,并加深人们对其在渗出性滑膜炎方面作用的了解,重点关注其副作用。
{"title":"Diacerein's Role in Alleviating Inflammation and Synovial Effusion in Knee Osteoarthritis: A Novel Therapeutic Approach","authors":"Saim Mahmood Khan,&nbsp;Marium Amjad,&nbsp;Rida Shakil,&nbsp;Eisha Shoaib,&nbsp;Dong Hwi Kim,&nbsp;Jawairya Muhammad Hussain","doi":"10.1002/med4.70004","DOIUrl":"https://doi.org/10.1002/med4.70004","url":null,"abstract":"<p>Diacerein, an anthraquinone derivative, has gained interest in recent years as a potential therapeutic agent in the management of knee osteoarthritis (KOA), particularly the inflammatory subtype effusion synovitis. This commentary evaluates the effect of diacerein on KOA symptoms and functional outcomes of recent parts of a multicenter randomized controlled trial. The clinical trial of diacerein as a monotherapy for effusion synovitis concluded that not only was there no overall significant change in the knee joint's moisture content after a 24-week therapy but also there was no evidence of symptomatic or functional improvement. Furthermore, problems like diarrhea and colored urine raised questions about its safety and user-friendly profile; therefore, these findings were contentious. These outcomes highlight the need for greater investigation of diacerein, including in combination therapies where its benefits are amplified and adverse effects diminished. Further research should help to define diacerein's role in KOA treatment and increase the understanding of its actions regarding effusion synovitis, focusing on side effects.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"54-56"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zelsuvmi Berdazimer—A Novel New Therapy for Molluscum Contagiosum—Efficacy, Safety, and Future Considerations Zelsuvmi berdazimer——一种治疗传染性软疣的新疗法——疗效、安全性和未来的考虑
Pub Date : 2025-03-12 DOI: 10.1002/med4.70003
Jawairya Muhammad Hussain, Sameen Suhail, Saim Mahmood Khan, Abdul Wasio

Berdazimer sodium, marketed as Zelsuvmi, is an antiviral medication used to treat a viral infection called molluscum contagiosum (MC). MC is a common skin infection caused by a poxvirus, resulting in round, stiff, but painless papules in various places on the body. Zelsuvmi's antiviral activity is associated with the release of nitric oxide, which exhibits potent antiviral properties. Zelsuvmi is used topically by patients or caregivers to treat this extremely contagious viral skin infection at home or in medical facilities. On January 5, 2024, the U.S. Food and Drug Administration approved Zelsuvmi for treating this infection in target populations, including adults and patients aged 1 year and above. Other therapies for MC, such as retinoic acid, benzoyl peroxide, and cryotherapy, are quite painful, while Zelsuvmi is less painful. The purpose of this article is to highlight the clinical importance and potential benefits of Zelsuvmi in the treatment of MC worldwide.

Berdazimer钠,以Zelsuvmi销售,是一种抗病毒药物,用于治疗一种叫做传染性软疣(MC)的病毒感染。MC是一种常见的皮肤感染,由痘病毒引起,导致身体各处出现圆形,僵硬但无痛的丘疹。Zelsuvmi的抗病毒活性与一氧化氮的释放有关,一氧化氮表现出强大的抗病毒特性。Zelsuvmi是患者或护理人员在家中或医疗机构治疗这种极具传染性的病毒性皮肤感染的局部用药。2024年1月5日,美国食品和药物管理局批准Zelsuvmi用于治疗目标人群中的这种感染,包括成人和1岁及以上的患者。其他治疗MC的方法,如视黄酸、过氧化苯甲酰和冷冻疗法,都是相当痛苦的,而Zelsuvmi则不那么痛苦。本文的目的是强调Zelsuvmi在全球范围内治疗MC的临床重要性和潜在益处。
{"title":"Zelsuvmi Berdazimer—A Novel New Therapy for Molluscum Contagiosum—Efficacy, Safety, and Future Considerations","authors":"Jawairya Muhammad Hussain,&nbsp;Sameen Suhail,&nbsp;Saim Mahmood Khan,&nbsp;Abdul Wasio","doi":"10.1002/med4.70003","DOIUrl":"https://doi.org/10.1002/med4.70003","url":null,"abstract":"<p>Berdazimer sodium, marketed as Zelsuvmi, is an antiviral medication used to treat a viral infection called molluscum contagiosum (MC). MC is a common skin infection caused by a poxvirus, resulting in round, stiff, but painless papules in various places on the body. Zelsuvmi's antiviral activity is associated with the release of nitric oxide, which exhibits potent antiviral properties. Zelsuvmi is used topically by patients or caregivers to treat this extremely contagious viral skin infection at home or in medical facilities. On January 5, 2024, the U.S. Food and Drug Administration approved Zelsuvmi for treating this infection in target populations, including adults and patients aged 1 year and above. Other therapies for MC, such as retinoic acid, benzoyl peroxide, and cryotherapy, are quite painful, while Zelsuvmi is less painful. The purpose of this article is to highlight the clinical importance and potential benefits of Zelsuvmi in the treatment of MC worldwide.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"50-53"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing the Diagnostic Performance of [18F]PSMA-1007 With [68Ga]Ga-PSMA-11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer [18F]PSMA-1007与[68Ga]Ga-PSMA-11在前列腺癌复发的PET/CT诊断及分期中的比较
Pub Date : 2025-03-11 DOI: 10.1002/med4.70006
Negar Abdi, Miad Alsulami, Hamid Ghaznavi

PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate-specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga-PSMA-11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [18F]PSMA-1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA-radiotracer is better than the other. Both 68Ga and 18F-labeled PSMA-radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [18F]PSMA-1007 with that of [68Ga]Ga-PSMA-11 in the detection of recurrent prostate cancer and determination of its stage. We found that [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 showed similar diagnostic performance, with [18F]PSMA-1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.

PET/CT 能够靶向前列腺细胞特异性蛋白--前列腺特异性膜抗原 (PSMA),因此已成为诊断前列腺癌的参考标准成像方式。[68Ga]Ga-PSMA-11是一项重大进步,但由于其寿命短、图像模糊等局限性,[18F]PSMA-1007应运而生,它具有寿命长、图像更清晰等优点。本研究旨在比较[18F]PSMA-1007和[68Ga]Ga-PSMA-11在复发性前列腺癌的检测和分期中的有效性,因为目前还没有足够的证据来断定一种PSMA-放射示踪剂优于另一种。68Ga和18F标记的PSMA放射示踪剂在患者体内的检出率相似。因此,需要进行更多的研究,才能权威地得出结论,哪种放射性示踪剂在 PET/CT 诊断前列腺癌病灶方面性能最佳。在这篇综述中,我们重点比较了[18F]PSMA-1007与[68Ga]Ga-PSMA-11在检测复发性前列腺癌并确定其分期方面的效果。我们发现[18F]PSMA-1007和[68Ga]Ga-PSMA-11具有相似的诊断性能,其中[18F]PSMA-1007对原发性和转移性复发性前列腺癌的敏感性略高。不过,两种放射性核素之间的差异缺乏统计学意义,这表明它们的诊断准确性相当,因此可以根据可用性和成本效益互换使用。
{"title":"Comparing the Diagnostic Performance of [18F]PSMA-1007 With [68Ga]Ga-PSMA-11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer","authors":"Negar Abdi,&nbsp;Miad Alsulami,&nbsp;Hamid Ghaznavi","doi":"10.1002/med4.70006","DOIUrl":"https://doi.org/10.1002/med4.70006","url":null,"abstract":"<p>PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate-specific membrane antigen (PSMA), a protein specific to prostate cells. [<sup>68</sup>Ga]Ga-PSMA-11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [<sup>18</sup>F]PSMA-1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup>Ga]Ga-PSMA-11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA-radiotracer is better than the other. Both <sup>68</sup>Ga and <sup>18</sup>F-labeled PSMA-radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [<sup>18</sup>F]PSMA-1007 with that of [<sup>68</sup>Ga]Ga-PSMA-11 in the detection of recurrent prostate cancer and determination of its stage. We found that [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup>Ga]Ga-PSMA-11 showed similar diagnostic performance, with [<sup>18</sup>F]PSMA-1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"9-19"},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Adverse Effects of Combination Therapy of Mpox With Tecovirimat and Brincidofovir, and Individual Therapy With Tecovirimat 特可韦马与布瑞替福韦联合治疗m痘与特可韦马单独治疗的不良反应比较
Pub Date : 2025-03-10 DOI: 10.1002/med4.70007
Muhammad Affan Abid, Abdul Ahad, Muhammad Faizan Shaikh, Kazim Raza

This study evaluates the safety profile of tecovirimat monotherapy compared to its combination with brincidofovir for mpox treatment Brincidofovir is associated with hepatic toxicity, raising concerns about its clinical use Tecovirimat demonstrates a favorable safety profile with minimal side effects, making it a strong candidate for standalone mpox treatment Combining tecovirimat with brincidofovir may increase hepatic toxicity risks and impair drug absorption, necessitating careful consideration A retrospective UK study found that brincidofovir-treated patients experienced liver enzyme abnormalities and prolonged hospitalization, while those on tecovirimat had no major adverse effects Tecovirimat remains the preferred option for mpox management, but further studies are required to establish safer and more effective treatment strategies.

本研究评估了特可维理马特单药治疗与brincidofovir联合治疗mpox的安全性,brincidofovir与肝毒性相关,引起了对其临床使用的关注,特可维理马特显示出良好的安全性,副作用最小,使其成为单独mpox治疗的强有力候选者,特可维理马特与brincidofovir联合治疗可能增加肝毒性风险并损害药物吸收。英国的一项回顾性研究发现,brincidofovir治疗的患者出现肝酶异常和住院时间延长,而使用tecovirimat的患者没有重大不良反应,tecovirimat仍然是mpox治疗的首选,但需要进一步的研究来建立更安全、更有效的治疗策略。
{"title":"Comparison of Adverse Effects of Combination Therapy of Mpox With Tecovirimat and Brincidofovir, and Individual Therapy With Tecovirimat","authors":"Muhammad Affan Abid,&nbsp;Abdul Ahad,&nbsp;Muhammad Faizan Shaikh,&nbsp;Kazim Raza","doi":"10.1002/med4.70007","DOIUrl":"https://doi.org/10.1002/med4.70007","url":null,"abstract":"<p>This study evaluates the safety profile of tecovirimat monotherapy compared to its combination with brincidofovir for mpox treatment Brincidofovir is associated with hepatic toxicity, raising concerns about its clinical use Tecovirimat demonstrates a favorable safety profile with minimal side effects, making it a strong candidate for standalone mpox treatment Combining tecovirimat with brincidofovir may increase hepatic toxicity risks and impair drug absorption, necessitating careful consideration A retrospective UK study found that brincidofovir-treated patients experienced liver enzyme abnormalities and prolonged hospitalization, while those on tecovirimat had no major adverse effects Tecovirimat remains the preferred option for mpox management, but further studies are required to establish safer and more effective treatment strategies.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"57-58"},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agentic Large Language Models for Healthcare: Current Progress and Future Opportunities 医疗保健机构大型语言模型:当前进展和未来机遇
Pub Date : 2025-03-03 DOI: 10.1002/med4.70000
Han Yuan

Agentic large language models (LLMs) combine vanilla LLMs’ reasoning, planning, and reflecting acquired from vast pre-trained datasets with specialized tools to enhance problem-solving capabilities. To understand the current progress and future opportunities of agentic LLMs for healthcare, this commentary conducted a comprehensive literature search in PubMed and summarized key takeaways.

代理大型语言模型(llm)将从大量预训练数据集获得的普通llm的推理、规划和反映与专门的工具相结合,以增强解决问题的能力。为了了解医疗保健代理法学硕士的当前进展和未来机会,本评论在PubMed进行了全面的文献检索,并总结了关键要点。
{"title":"Agentic Large Language Models for Healthcare: Current Progress and Future Opportunities","authors":"Han Yuan","doi":"10.1002/med4.70000","DOIUrl":"https://doi.org/10.1002/med4.70000","url":null,"abstract":"<p>Agentic large language models (LLMs) combine vanilla LLMs’ reasoning, planning, and reflecting acquired from vast pre-trained datasets with specialized tools to enhance problem-solving capabilities. To understand the current progress and future opportunities of agentic LLMs for healthcare, this commentary conducted a comprehensive literature search in PubMed and summarized key takeaways.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"37-41"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toward the Comprehensive Evaluation of Medical Text Generation by Large Language Models: Programmatic Metrics, Human Assessment, and Large Language Models Judgment 面向大型语言模型医学文本生成的综合评价:程序化度量、人的评估和大型语言模型判断
Pub Date : 2025-02-28 DOI: 10.1002/med4.70002
Han Yuan

This commentary discusses three evaluation approaches for assessing large language models' generation in healthcare: programmatic metrics, human assessment, and large language models judgment. No single approach can address all challenges; however, the combination of these three methods provides a pipeline toward the comprehensive evaluation of medical text generation.

这篇评论讨论了评估医疗保健中大型语言模型生成的三种评估方法:程序化度量、人工评估和大型语言模型判断。没有一种方法可以解决所有挑战;然而,这三种方法的结合为医学文本生成的综合评价提供了一条管道。
{"title":"Toward the Comprehensive Evaluation of Medical Text Generation by Large Language Models: Programmatic Metrics, Human Assessment, and Large Language Models Judgment","authors":"Han Yuan","doi":"10.1002/med4.70002","DOIUrl":"https://doi.org/10.1002/med4.70002","url":null,"abstract":"<p>This commentary discusses three evaluation approaches for assessing large language models' generation in healthcare: programmatic metrics, human assessment, and large language models judgment. No single approach can address all challenges; however, the combination of these three methods provides a pipeline toward the comprehensive evaluation of medical text generation.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"46-49"},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pioneering Multidisciplinary Innovation: A Year in Review and Vision for the Future 开拓多学科创新:回顾和展望未来的一年
Pub Date : 2025-02-21 DOI: 10.1002/med4.90
Xueqing Yu
<p><i>Medicine Advances</i> is dedicated to driving multidisciplinary innovation and advancing global healthcare. Reflecting on our achievements in 2024 and looking ahead to the opportunities in 2025, we reaffirm our commitment to shaping the future of medicine through collaboration, innovation, and excellence.</p><p>In 2024, the journal achieved significant milestones. The share of international manuscripts rose to 40%, reflecting our growing global reach. Additionally, our indexation by the Directory of Open Access Journals (DOAJ) marked a pivotal step in enhancing accessibility to high-quality research. As we anticipate the release of our first Impact Factor in 2025, these accomplishments highlight our journal's expanding influence and dedication to advancing global medical science.</p><p>Healthcare is undergoing transformative changes, with interdisciplinary collaboration breaking traditional “silos” and enabling innovative solutions to complex medical challenges. The integration of engineering, computational sciences, and behavioral research is driving advancements in diagnostics and treatments. Multimodal frameworks that combine imaging, biomarkers, and clinical data empower clinicians to treat diseases with unprecedented precision and depth. Over the past year, we have embraced these trends, actively promoting interdisciplinary collaboration. Our upcoming special issue on cardio-renal syndrome reflects this approach, exploring the complexities of multidisciplinary medicine from a holistic perspective.</p><p>Similarly, the convergence of multi-omics and systems biology is reshaping precision medicine. By integrating genomics, proteomics, metabolomics, and epigenomics, we gain holistic insights into disease mechanisms and therapeutic targets. Multi-omics approaches are transforming oncology, enabling dynamic understanding of tumor heterogeneity and guiding adaptive treatments. <i>Medicine Advances</i> is at the forefront of this transformation, prioritizing studies that bridge the gap between research and clinical care. To support this mission, we are preparing a special issue on multi-omics advancements, showcasing cutting-edge innovations.</p><p>The 2024 Nobel Prize, awarded for breakthroughs in artificial intelligence (AI) applied to protein design and structure prediction, underscores AI's transformative role in healthcare. By accelerating drug discovery, enhancing diagnostic accuracy in medical imaging, and enabling tailored treatment plans through personalized medicine, AI is reshaping the medical landscape. To delve deeper into these innovations, we are preparing a special issue on exploring the true color of AI in its role of supporting the medical imaging in cancer evolution. We aim to highlight AI's role in understanding cancer progression, improving diagnostic precision, and guiding personalized therapies. By bringing together insights from oncology, imaging technology, and computational science, the issue seeks to foster interdis
医学进展》致力于推动多学科创新,促进全球医疗保健事业的发展。回顾2024年的成就,展望2025年的机遇,我们重申致力于通过合作、创新和卓越塑造医学的未来。国际稿件的比例上升到了40%,反映出我们的全球影响力在不断扩大。此外,我们被《开放获取期刊目录》(DOAJ)收录,标志着我们在提高高质量研究的可获取性方面迈出了关键一步。随着我们预计在2025年发布第一个影响因子,这些成就彰显了我们期刊不断扩大的影响力和对推动全球医学科学发展的奉献精神。医疗保健领域正在经历变革,跨学科合作打破了传统的 "孤岛",为应对复杂的医学挑战提供了创新解决方案。工程学、计算科学和行为研究的融合正在推动诊断和治疗的进步。结合成像、生物标记和临床数据的多模态框架使临床医生能够以前所未有的精度和深度治疗疾病。在过去的一年里,我们顺应这些趋势,积极推动跨学科合作。我们即将出版的心肾综合征特刊反映了这一方法,从整体角度探讨了多学科医学的复杂性。同样,多组学和系统生物学的融合正在重塑精准医学。通过整合基因组学、蛋白质组学、代谢组学和表观基因组学,我们获得了对疾病机制和治疗目标的整体认识。多组学方法正在改变肿瘤学,使我们能够动态了解肿瘤的异质性并指导适应性治疗。医学进展》站在这一变革的前沿,优先考虑那些能够弥合研究与临床治疗之间差距的研究。为了支持这一使命,我们正在准备一期关于多组学进展的特刊,展示最前沿的创新成果。2024 年诺贝尔奖因人工智能(AI)在蛋白质设计和结构预测方面的突破而颁发,这突显了人工智能在医疗保健领域的变革性作用。通过加速药物发现、提高医学影像诊断的准确性,以及通过个性化医疗实现量身定制的治疗方案,人工智能正在重塑医疗格局。为了深入探讨这些创新,我们正在准备一期特刊,探讨人工智能在癌症进化过程中支持医学影像的作用,揭示人工智能的真面目。我们的目标是突出人工智能在了解癌症进展、提高诊断精准度和指导个性化治疗方面的作用。本期杂志汇集了肿瘤学、成像技术和计算科学的真知灼见,旨在促进跨学科对话,推动人工智能在临床护理中的实际应用。除临床进步外,人工智能还通过简化操作、改善疾病管理以及通过预测分析增强公共卫生来优化医疗保健系统。随着人工智能不断给医疗保健带来革命性的变化,道德和公平的实施对于确保其在全球范围内产生可持续和包容性的影响至关重要。通过策划高影响力的研究和促进全球合作,我们的目标是创造一个医学更加精确、更具包容性和影响力的未来。作为主编,我衷心感谢我们的作者、审稿人和编辑团队的不懈努力。你们的贡献对我们的成功和促进多学科医学研究的使命功不可没。我们正在共同推进医学科学前沿的发展,并对全球医疗保健产生有意义的影响。余学清:构思、写作-原稿、写作-审阅和编辑。作者声明没有利益冲突。
{"title":"Pioneering Multidisciplinary Innovation: A Year in Review and Vision for the Future","authors":"Xueqing Yu","doi":"10.1002/med4.90","DOIUrl":"https://doi.org/10.1002/med4.90","url":null,"abstract":"&lt;p&gt;&lt;i&gt;Medicine Advances&lt;/i&gt; is dedicated to driving multidisciplinary innovation and advancing global healthcare. Reflecting on our achievements in 2024 and looking ahead to the opportunities in 2025, we reaffirm our commitment to shaping the future of medicine through collaboration, innovation, and excellence.&lt;/p&gt;&lt;p&gt;In 2024, the journal achieved significant milestones. The share of international manuscripts rose to 40%, reflecting our growing global reach. Additionally, our indexation by the Directory of Open Access Journals (DOAJ) marked a pivotal step in enhancing accessibility to high-quality research. As we anticipate the release of our first Impact Factor in 2025, these accomplishments highlight our journal's expanding influence and dedication to advancing global medical science.&lt;/p&gt;&lt;p&gt;Healthcare is undergoing transformative changes, with interdisciplinary collaboration breaking traditional “silos” and enabling innovative solutions to complex medical challenges. The integration of engineering, computational sciences, and behavioral research is driving advancements in diagnostics and treatments. Multimodal frameworks that combine imaging, biomarkers, and clinical data empower clinicians to treat diseases with unprecedented precision and depth. Over the past year, we have embraced these trends, actively promoting interdisciplinary collaboration. Our upcoming special issue on cardio-renal syndrome reflects this approach, exploring the complexities of multidisciplinary medicine from a holistic perspective.&lt;/p&gt;&lt;p&gt;Similarly, the convergence of multi-omics and systems biology is reshaping precision medicine. By integrating genomics, proteomics, metabolomics, and epigenomics, we gain holistic insights into disease mechanisms and therapeutic targets. Multi-omics approaches are transforming oncology, enabling dynamic understanding of tumor heterogeneity and guiding adaptive treatments. &lt;i&gt;Medicine Advances&lt;/i&gt; is at the forefront of this transformation, prioritizing studies that bridge the gap between research and clinical care. To support this mission, we are preparing a special issue on multi-omics advancements, showcasing cutting-edge innovations.&lt;/p&gt;&lt;p&gt;The 2024 Nobel Prize, awarded for breakthroughs in artificial intelligence (AI) applied to protein design and structure prediction, underscores AI's transformative role in healthcare. By accelerating drug discovery, enhancing diagnostic accuracy in medical imaging, and enabling tailored treatment plans through personalized medicine, AI is reshaping the medical landscape. To delve deeper into these innovations, we are preparing a special issue on exploring the true color of AI in its role of supporting the medical imaging in cancer evolution. We aim to highlight AI's role in understanding cancer progression, improving diagnostic precision, and guiding personalized therapies. By bringing together insights from oncology, imaging technology, and computational science, the issue seeks to foster interdis","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.90","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicine Advances
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1